Business
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. The live webcasts may be accessed under the Investors tab on www.
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J.4IvnfhFM_bTHIo4TE3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"text","content":"NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.","length":434,"tagName":"p"},{"type":"text","content":"The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.","length":124,"tagName":"p"},{"type":"text","content":"About Acumen Pharmaceuticals, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. ","length":822,"tagName":"p"},{"type":"text","content":"Investors: Alex [email protected]","length":45,"tagName":"p"},{"type":"text","content":"Media: [email protected]","length":35,"tagName":"p"},{"type":"text","content":"...